Nicox Ophthalmics develops therapeutics from a proprietary nitric-oxide research platform to help maintain vision and improve ocular health.
Employment range in NC
Primary site activity
All company activities
Products on market
VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is commercialized in more than 15 countries, including the U.S.; ZERVIATE® in allergic conjunctivitis is commercialized in the U.S. by Harrow Health Inc.
Products under development
NCX 470 in Phase 3 clinical development for IOP lowering for patients with open-angle glaucoma and ocular hypertension; NCX 1728 in preclinical development for retinal conditions